Related Experiment Videos
Single dose aztreonam in treating gonorrhoea
Genitourinary Medicine
|February 1, 1987
Summary
Aztreonam effectively cured urogenital gonorrhea in 100% of patients. However, treatment failures occurred in rectal and pharyngeal sites, despite no observed in vitro resistance to this antibiotic.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Gonorrhea remains a significant public health concern globally.
- Antimicrobial resistance in Neisseria gonorrhoeae necessitates the evaluation of alternative treatment options.
- Aztreonam is a monobactam antibiotic with activity against Gram-negative bacteria.
Purpose of the Study:
- To evaluate the efficacy and safety of a single intramuscular dose of aztreonam for treating urogenital gonorrhea.
- To assess treatment outcomes at different anatomical sites, including rectal and pharyngeal infections.
Main Methods:
- A prospective study involving 108 consecutive patients diagnosed with urogenital gonorrhea.
- Treatment administered as a single 1g intramuscular dose of aztreonam.
- Clinical and microbiological evaluation of 102 patients post-treatment.
Main Results:
- A 100% cure rate was achieved at urogenital sites.
- Treatment failure was observed in 3 out of 14 (21%) patients with rectal or pharyngeal gonorrhea.
- No instances of in vitro aztreonam resistance were detected among the evaluated isolates.
Conclusions:
- Single intramuscular dose of aztreonam demonstrates high efficacy for urogenital gonorrhea.
- Efficacy may be reduced for non-urogenital sites like the rectum and pharynx.
- Further investigation is warranted for aztreonam's role in treating resistant gonorrhea strains.